RA Capital infuses fresh cash into vaccine patch developer after promising data


The money follows positive results from an early-stage trial of a patch that delivers a flu vaccine through the skin, developed by Vaxess Technologies.

Previous What's in store for 2023? These D.C.-area business leaders offer their takes — and resolutions
Next Editorial: Biotechs seeking FDA approval must prioritize transparency